跳至主要内容
临床试验/CTRI/2022/12/047860
CTRI/2022/12/047860尚未招募3 期

A prospective, randomized, open-label, active-controlled, clinical study to evaluate the tolerability and incidence of pregnancy complications up on Lipocal supplementation in pregnant women

G.C Chemie Pharmie Limited1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2022年5月12日最近更新:

试验速览

阶段
3 期
状态
尚未招募
发起方
入组人数
40
试验地点
1
主要终点
1. Modified Bovenschen GI Symptoms Questionnaire

研究概览

简要总结

Physiological changes occur in pregnancy and maintaining maternal homeostasis and enabling fetal growth and development have direct association on calcium metabolism. Increased intestinal calcium absorption, increased urine calcium excretion, and increased bone turnover are all part of the calcium homeostatic response during pregnancy. From 6th month onwards, with the third trimester being bulk of calcium utilized, when fetal skeletal growth peaks at 250 to 350 milligrams transferred from pregnant mother and baby every day. Pregnant women’s daily calcium consumption has been reported to be low. WHO recommends 1.5 g to 2 g daily for pregnant women with low dietary calcium intake. Calcium supplementation during pregnancy for women who do not get enough calcium from their diet has a significant benefit in reducing preeclampsia and preterm births, as well as enhancing maternal and child bone health.

研究设计

研究类型
Interventional
分配方式
Permuted block randomization, fixed
盲法
Open Label

入排标准

年龄范围
18.00 Year(s) 至 40.00 Year(s)(—)
性别
Female

入选标准

  • Pregnant females between the ages of ≥18 and 40 years (both inclusive) willing to participate in study and provide written informed consent.
  • Pregnant women at 20th weeks attending antenatal care visit (ANC) visit at study clinics.

排除标准

  • No medical contraindications to continuing pregnancy.
  • Treatment with antitubercular and anti-epileptic drugs.
  • History of pre-eclampsia & eclampsia
  • Prior diagnosis of parathyroid disorder or thyroidectomy
  • Diseases that require digoxin, phenytoin, or tetracycline therapy
  • History of chronic liver disease
  • History of renal disease & no known uterine anomaly
  • No history of cervical conization
  • Obesity (BMI 30.0 and higher)
  • Diagnostic history of Type I & Type II Diabetes
  • Diagnostic history of hypertension
  • Subject with multiple pregnancy.
  • Any other condition that in the opinion of the investigator does not justify the patients participation in the study.

结局指标

主要结局

1. Modified Bovenschen GI Symptoms Questionnaire

时间窗: 1. visit 1, visit 2, visit 3, visit 4, visit 5, visit 6, visit 7, visit 8, visit 9. | 2. visit 1, visit 2, visit 3, visit 4, visit 5, visit 6, visit 7, visit 8, visit 9.

2. Tolerability assessed via a five-point Facial Hedonic Scale for

时间窗: 1. visit 1, visit 2, visit 3, visit 4, visit 5, visit 6, visit 7, visit 8, visit 9. | 2. visit 1, visit 2, visit 3, visit 4, visit 5, visit 6, visit 7, visit 8, visit 9.

Taste (palatability) Swallowability Mouthfeel (texture) & Smell

时间窗: 1. visit 1, visit 2, visit 3, visit 4, visit 5, visit 6, visit 7, visit 8, visit 9. | 2. visit 1, visit 2, visit 3, visit 4, visit 5, visit 6, visit 7, visit 8, visit 9.

次要结局

  • Information of any diagnosed preeclampsia during unscheduled ANC visit(visit 1, visit 2, visit 3, visit 4, visit 5, visit 6, visit 7, visit 8 and visit 9.)
  • Still birth(Throughout the study)
  • Early preterm birth(Start of study and up to 32 weeks)
  • Preeclampsia
  • Neonatal death(visit 9)
  • Perinatal death(visit 6, visit 7, visit 8 and visit 9)
  • Bristol Stool Questionnaire(visit 1, visit 2, visit 3, visit 4, visit 5, visit 6, visit 7, visit 8, visit 9)
  • Preterm Birth(Throughout the study)
  • Placental abruption with grade(Throughout the study)
  • IUGR(visit 1, visit 5, visit 6, visit 7, visit 8 and visit 9.)
  • Low birth weight(Throughout the study)
  • Small for gestational age birth(visit 1, visit 5, visit 6, visit 7, visit 8 and visit 9)

研究者

发起方
G.C Chemie Pharmie Limited
申办方类型
Pharmaceutical industry-Indian

研究点 (1)

Loading locations...

相似试验